- Home
- EML vs CABA Comparison
EML vs CABA Comparison
Compare EML & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EML
- CABA
- Stock Information
- Founded
- EML 1858
- CABA 2017
- Country
- EML United States
- CABA United States
- Employees
- EML N/A
- CABA N/A
- Industry
- EML Industrial Machinery/Components
- CABA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EML Consumer Discretionary
- CABA Health Care
- Exchange
- EML Nasdaq
- CABA Nasdaq
- Market Cap
- EML 144.5M
- CABA 149.3M
- IPO Year
- EML N/A
- CABA 2019
- Fundamental
- Price
- EML $23.50
- CABA $1.57
- Analyst Decision
- EML
- CABA Strong Buy
- Analyst Count
- EML 0
- CABA 7
- Target Price
- EML N/A
- CABA $14.43
- AVG Volume (30 Days)
- EML 8.4K
- CABA 1.3M
- Earning Date
- EML 08-05-2025
- CABA 08-07-2025
- Dividend Yield
- EML 1.86%
- CABA N/A
- EPS Growth
- EML N/A
- CABA N/A
- EPS
- EML N/A
- CABA N/A
- Revenue
- EML $271,440,503.00
- CABA N/A
- Revenue This Year
- EML $1.56
- CABA N/A
- Revenue Next Year
- EML $7.00
- CABA N/A
- P/E Ratio
- EML $11.20
- CABA N/A
- Revenue Growth
- EML 8.15
- CABA N/A
- 52 Week Low
- EML $19.06
- CABA $0.99
- 52 Week High
- EML $35.03
- CABA $7.27
- Technical
- Relative Strength Index (RSI)
- EML 51.73
- CABA 43.15
- Support Level
- EML $23.21
- CABA $1.58
- Resistance Level
- EML $23.70
- CABA $1.74
- Average True Range (ATR)
- EML 0.49
- CABA 0.09
- MACD
- EML -0.03
- CABA 0.00
- Stochastic Oscillator
- EML 47.03
- CABA 4.55
About EML Eastern Company (The)
The Eastern Co manages industrial businesses that design, manufacture, and sell engineered solutions to industrial markets. The company manages the financial, operational, and strategic performance of its businesses to increase cash generation, operating earnings, and long-term shareholder value. It operates in the United States and Other Countries and generates the majority of its revenue from the United States.
About CABA Cabaletta Bio Inc.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.